Profile of NOVAVAX INC(NASDAQ:NVAX) stock

NOVAVAX INC11.29

NASDAQ:NVAX (1/27/2023, 7:25:13 PM)+0.31 (+2.82%)

Premarket: 11.19 -0.1 (-0.89%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS Sector	Health Care
GICS Industry	Biotechnology

Chartmill FA Rating

Valuation		Growth
Profitability		Health
Dividend

Overview

Earnings (Last)	11-08 2022-11-08/amc	Earnings (Next)	02-27 2023-02-27
Ins Owners	0.26%	Inst Owners	43.82%
Market Cap	959.70M	Shares	85.00M
PE	N/A	Fwd PE	N/A
Dividend Yield	N/A	Analysts	74.29
IPO	05-16 1973-05-16

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 1,541 full-time employees. The firm promotes improved health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its recombinant technology platform harnesses the power and speed of genetic engineering to produce immunogenic nanoparticles designed to address urgent global health needs. The vaccine candidates in its near-term pipeline, including both coronavirus vaccine candidate (NVX-CoV2373) and seasonal quadrivalent influenza vaccine candidate (NanoFlu), which are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 is marketed under the brand name of Covovax or as Nuvaxovid COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]).

Company Info

NOVAVAX INC

21 Firstfield Road

Gaithersburg MARYLAND 20878

P: 12402682000.0

CEO: Stanley C. Erck

Employees: 1541

Website: https://www.novavax.com/

NVAX News

3 days ago - Investor's Business DailyNovavax Jumps After Pledging To Update Its Covid Shot; Pfizer, Moderna Slip

The FDA's experts voted in favor of annual boosters on Thursday.

3 days ago - The Motley Fool3 Great Growth Stocks Down 20% or More to Buy Now

These beaten-down stocks could be poised for major rebounds.

4 days ago - Market News VideoNVAX March 10th Options Begin Trading

5 days ago - Novavax, Inc.Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...

5 days ago - The Motley FoolThis Investment Strategy Would Have Reduced Your Novavax Losses by 20% Last Year

If you want to invest in volatile stocks, a certain strategy can minimize your overall risk.

6 days ago - The Motley Fool3 Remarkable Stocks That Can Burn Short-Sellers Big-Time in 2023

Exceptionally high short interest in these innovative and transformative businesses may lead to a short squeeze.

NOVAVAX INC (NVAX) 11.29 +0.31 (+2.82%)

11.29 +0.31 (+2.82%)